NCT05615623 2026-04-21
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
InSightec
Phase 1/2 Active not recruiting
Clinical Trials
273 trialsNCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
NCT06413706 2026-04-20
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
Phase 2 Active not recruiting
NCT05630209 2026-04-17
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
InSightec
Phase 1/2 Active not recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT04762069 2026-04-15
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT07326566 2026-04-14
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT04988750 2026-04-13
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NaviFUS Corporation
Phase NA Completed
NCT06012695 2026-04-13
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT06253871 2026-04-13
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
Phase 1 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05538130 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT03714243 2026-03-20
BBBD
InSightec
Phase NA Completed
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT02568267 2026-03-06
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT05593094 2026-02-25
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT07428616 2026-02-24
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Not yet recruiting
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT04739761 2026-02-11
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT06057168 2026-01-29
GDX-44-016
Guerbet
Phase 3 Completed
NCT06458712 2026-01-16
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Duke Street Bio Ltd
Phase 1 Recruiting
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT03423628 2025-12-22
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase 1 Recruiting
NCT06098248 2025-12-15
cCeLLExvivo
VPIX Medical
Phase NA Terminated
NCT07274397 2025-12-10
EARLYBRAINPET
Beta Emitting Accurate Monitored Systems
Phase NA Not yet recruiting
NCT05256290 2025-12-09
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics, Inc.
Phase 1/2 Active not recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT06764940 2025-11-28
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting
NCT07254845 2025-11-28
A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS
VPIX Medical
Phase 1 Not yet recruiting
NCT06777433 2025-11-24
RAD101
Radiopharm Theranostics, Ltd
Phase 2 Recruiting
NCT02831959 2025-10-31
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
NovoCure Ltd.
Phase 3 Completed
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT04712721 2025-10-10
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Novartis
Phase EARLY_PHASE1 Terminated
NCT04365374 2025-10-07
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Phase 3 Active not recruiting
NCT06136884 2025-10-01
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A2A Pharmaceuticals Inc.
Phase 1 Recruiting
NCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT05023551 2025-09-16
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Sumitomo Pharma America, Inc.
Phase EARLY_PHASE1 Active not recruiting
NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed